Bioject sees PATH to developing world market:
This article was originally published in Clinica
Bioject Medical Technologies is to collaborate with PATH, a Seattle, Washington-based public health organisation, on the development of a needle-free, single-dose cartridge immunisation system. Under the agreement, PATH will evaluate the system using a combination of performance-based bench testing and user focus groups in the developing world. Data from this evaluation will be used to demonstrate the benefits of this technology and reintroduce it to this market, says Bedminster, New Jersey-based Bioject.